Evaluation of Escherichia coli Membrane Preparations of Canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with Coexpressed Canine Cytochrome P450 Reductase
Authors:
- Charles W. LocusonCLCharles W. Locuson
- Brian T. EthellBEBrian T. Ethell
- Michael VoiceMVMichael Voice
- David LeeDLDavid Lee
- Kenneth L. FeenstraKFKenneth L. Feenstra
Open Access
- 1 March 2009
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 37 (3) , 457-461
Abstract
The preparation of bacterial membranes (“Bactosomes”) containing expressed canine (beagle) hepatic cytochromes P450 (P450s) is described. cDNAs from seven canine P450s were subcloned into inducible expression plasmids and, for the first time, cotransformed and expressed with a canine P450 oxidoreductase in Escherichia coli to produce active, full-length, native sequence P450s. Enzyme expression levels, although variable, were generally sufficient to enable short incubation times and to limit the total protein present in enzyme incubations. Steady-state kinetics of CYP1A1, 2C21, and 2D15 Bactosomes demonstrated similarities with dog liver microsomes or Baculosomes. However, 3A12 lacked substrate inhibition in the formation of 1′-OH midazolam, and 2B11 displayed non-Michaelis-Menten kinetics, suggesting possible differences in protein interaction effects. In monitoring the metabolites of common P450 substrates, phenacetin deethylation, temazepam demethylation, and bufuralol 1′-hydroxylation were shown to be relatively selective reactions catalyzed by CYP1A1, 2B11, and 2D15, respectively. 1′-OH midazolam was formed in higher quantities by CYP2B11 and 2C21 than by 3A12, raising questions about the use of midazolam as a CYP3A12 probe in vivo. In summary, a panel of recombinant P450s was produced to make up for the lack of commercially available canine P450 isoforms. The Bactosomes are expected to facilitate reaction phenotyping and metabolic drug-drug interaction assessment in canine drug development and to enable the study of interspecies differences in P450-mediated drug metabolism.Keywords
This publication has 22 references indexed in Scilit:
- In Vitro Drug-Drug Interaction Screens for Canine Veterinary Medicines: Evaluation of Cytochrome P450 Reversible InhibitionDrug Metabolism and Disposition, 2008
- Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug InteractionsDrug Metabolism and Disposition, 2008
- Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: A comparative studyin vitroXenobiotica, 2007
- Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant EnzymesDrug Metabolism and Disposition, 2006
- Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12The Journal of Pharmacology and Experimental Therapeutics, 2005
- SUBSTRATE SPECIFICITY AND KINETIC PROPERTIES OF SEVEN HETEROLOGOUSLY EXPRESSED DOG CYTOCHROMES P450Drug Metabolism and Disposition, 2003
- Issues Related to the Use of Canines in Toxicologic Pathology—Issues With Pharmacokinetics and MetabolismToxicologic Pathology, 2003
- Functional co-expression of CYP2D6 and human NADPHcytochrome P450 reductase in Escherichia coliPharmacogenetics, 1998
- Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coliFEBS Letters, 1996
- Quantitation of cytochrome P450 enzymes (CYP1A1/2, 2B11, 2C21 and 3A12) in dog liver microsomes by enzyme-linked immunosorbent assayXenobiotica, 1996